The prescribing guidance, formularies, pathways and information on this website have transferred from the predecessor organisations that now form NHS Central East ICB.
Guidance may not be available for all clinical topics or geographic areas. Where guidance is available, it is clearly identified as applying to Bedfordshire, Luton and Milton Keynes (BLMK), Cambridgeshire and Peterborough (C&P), Hertfordshire or Central East (CE).
Guidance labelled Central East (CE) has been harmonised and approved for use across NHS Central East ICB. Where CE guidance is not available, local arrangements for BLMK, C&P or Hertfordshire remain in place.
For Hertfordshire prescribing guidance, please visit: www.hweclinicalguidance.nhs.uk
Bedfordshire, Luton and Milton Keynes
The Shared Care Guideline below was developed by Cambridgeshire and Peterborough and has been ratified for use in Bedfordshire, Luton and Milton Keynes for patients receiving care from Cambridge University Hospitals NHS Foundation Trust (CUHFT).
Cambridgeshire and Peterborough
Alemtuzumab for relapsing-remitting multiple sclerosis – Shared Care Guidance (pdf)